Cutaneous graft-versus-host disease: Rationales and treatment options

Dermatologic Therapy

Volumn 24, Issue 2, 2011, Pages 219-228

  Chavan, Rahul ^a   El Azhary, Rokea ^a  

^a MAYO CLINIC   (United States)

Author keywords

Graft versus host disease; GVHD treatment

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG MEGADOSE; ENGRAFTMENT SYNDROME; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; LUNG EMBOLISM; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRESCRIPTION; PROPHYLAXIS; SEPSIS; SIDE EFFECT; SKIN GRAFT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ACUTE DISEASE; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; SKIN; SKIN DISEASES; TREATMENT OUTCOME;

EID: 79952766447     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2011.01397.x     Document Type: Article

References (54)

1. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002: 100: 406-414. (Pubitemid 34761100)
2. Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009: 114: 702-708.
3. Filipovich AH. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008: 21: 251-257. (Pubitemid 351712714)
4. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005: 11: 945-956.
5. Pollack SM, O'Connor TP, Jr, Hashash J, Tabbara IA. Non-myeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review. Am J Clin Oncol 2009: 32: 618-628.
6. Bornhauser M, Schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999: 67: 499-504. (Pubitemid 29114207)
7. Horowitz MM, Przepiorka D, Bartels P, et al. Tacrolimus versus cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biol Blood Marrow Transplant 1999: 5: 180-186.
8. Mohty M, de Lavallade H, Faucher C, et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004: 34: 527-530. (Pubitemid 39264044)
9. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000: 96: 2062-2068.
10. Ram R, Gafter-Gvili A, Yeshurun M, et al. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009: 43: 643-653.
11. Wolff D, Andree H, Hilgendorf I, et al. Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation - timing and conditioning regimen may be crucial. Biol Blood Marrow Transplant 2008: 14: 942-943. (Pubitemid 351985023)
12. Storb R, Antin JH, Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant 2010: 16: S18-S27.
13. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992: 80: 2964-2968. (Pubitemid 23004498)
14. Reddy P, Maeda Y, Liu C, et al. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005: 11: 1244-1249. (Pubitemid 43093673)
15. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant 2009: 45: 1-11.
16. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol 1998: 134: 602-612. (Pubitemid 28222313)
17. Hausermann P, Walter RB, Halter J, et al. Cutaneous graft-versus-host disease: a guide for the dermatologist. Dermatology 2008: 216: 287-304. (Pubitemid 351630093)
18. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001: 27: 893-898. (Pubitemid 32529870)
19. Saliba RM, de Lima M, Giralt S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007: 109: 2751-2758. (Pubitemid 46482067)
20. Meves A, el-Azhary RA, Talwalkar JA, et al. Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. J Am Acad Dermatol 2006: 55: 642-646. (Pubitemid 44467989)
21. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Rev 2006: 20: 15-27. (Pubitemid 43106715)
22. Hymes SR, Turner ML, Champlin RE, Couriel DR. Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2006: 12: 1101-1113. (Pubitemid 44660866)
23. Aractingi S, Socie G, Devergie A, Dubertret L, Gluckman E. Localized scleroderma-like lesions on the legs in bone marrow transplant recipients: association with polyneuropathy in the same distribution. Br J Dermatol 1993: 129: 201-203. (Pubitemid 23250738)
24. Bingham LG, Noble JW, Davis MD. Wet dressings used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol 2009: 60: 792-800.
25. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-versus-host disease: a case series of 18 patients. Arch dermatol 2001: 137: 1202-1206. (Pubitemid 32847843)
26. Sanchez AR, Sheridan PJ, Rogers RS. Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol 2004: 75: 613-619. (Pubitemid 38635033)
27. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002: 8: 387-394.
28. Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001: 98: 1622-1625.
29. Lamioni A, Parisi F, Isacchi G, et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005: 79: 846-850. (Pubitemid 40546206)
30. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003: 102: 470-476. (Pubitemid 36841962)
31. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008: 112: 1515-1521.
32. Di Renzo M, Rubegni P, Pasqui AL, et al. Extracorporeal photopheresis affects interleukin (IL)-10 and IL-12 production by monocytes in patients with chronic graft-versus-host disease. Br J Dermatol 2005: 153: 59-65. (Pubitemid 41044528)
33. Shaughnessy PJ, Bolwell BJ, van Besien K, et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2009: 45: 1068-1076.
34. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006: 91: 405-408.
35. Baird K, Wayne AS. Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease. Transfus Apher Sci 2009: 41: 209-216.
36. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005: 35: 1187-1193. (Pubitemid 40895175)
37. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008: 112: 2667-2674.
38. Grundmann-Kollmann M, Behrens S, Gruss C, et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000: 42: 134-136. (Pubitemid 30470334)
39. Stander H, Schiller M, Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002: 46: 799-800.
40. Wetzig T, Sticherling M, Simon JC, et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005: 35: 515-519. (Pubitemid 40403356)
41. Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol 2004: 4: 11.
42. Brazzelli V, Grasso V, Muzio F, et al. Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. Br J Dermatol 2010: 162: 404-409.
43. Grundmann-Kollmann M, Martin H, Ludwig R, et al. Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation 2002: 74: 1631-1634. (Pubitemid 36014239)
44. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987: 166: 1280-1289. (Pubitemid 18051422)
45. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008: 111: 2470-2475. (Pubitemid 351451462)
46. Alousi AM,W eisdorf DJ, Logan BR, et al. Etanercept,mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009: 114: 511-517.
47. Couriel DR, Saliba R, de Lima M, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009: 15: 1555-1562.
48. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004: 104: 1224-1226. (Pubitemid 39038048)
49. Shaughnessy PJ, Bachier C, Grimley M, et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005: 11: 188-193. (Pubitemid 40287917)
50. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002: 8: 117-130. (Pubitemid 34285070)
51. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 2003: 139: 39-43. (Pubitemid 36091572)
52. Fromowitz JS, Ramos-Caro FA, Flowers FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 2007: 46: 1092-1094. (Pubitemid 47506383)
53. Fatourechi MM, el-Azhary RA, Gibson LE. Rituximab: applications in dermatology. Int J Dermato 2006: 45: 1143-1155. quiz 55.
54. Arai S, Miklos DB. Rituximab in hematopoietic cell transplantation. Expert Opin Biol Ther 2010: 10: 971-982.